These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: NFIX downregulation independently predicts poor prognosis in lung adenocarcinoma, but not in squamous cell carcinoma.
    Author: Ge J, Dong H, Yang Y, Liu B, Zheng M, Cheng Q, Peng L, Li J.
    Journal: Future Oncol; 2018 Dec; 14(30):3135-3144. PubMed ID: 30418046.
    Abstract:
    AIM: To study the expression profile of NFIX, its prognostic value and the mechanism of its dysregulation in lung adenocarcinoma (LUAD). Patients & materials: A retrospective study was performed by using data from the Cancer Genome Atlas and the Human Protein Atlas. RESULTS: High NFIX RNA expression was an independent prognostic factor of favorable overall survival (HR: 0.687, 95% CI: 0.496-0.951; p = 0.024) and recurrence-free survival (HR: 0.700, 95% CI: 0.493-0.994, p = 0.046) in LUAD, but not in lung squamous cell carcinoma. NFIX DNA hypermethylation was associated with significantly decreased NFIX expression and shorter overall survival and recurrence-free survival in LUAD. CONCLUSION:  NFIX downregulation might independently predict poor prognosis in LUAD. DNA hypermethylation might be an important cause of the downregulation.
    [Abstract] [Full Text] [Related] [New Search]